INVOCARE LIMITED (IVC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IVC - INVOCARE LIMITED

FNArena Sector : Consumer Products & Services
Year End: December
GICS Industry Group : Consumer Services
Debt/EBITDA: 3.33
Index: ASX200 | ASX300 | ALL-ORDS

InvoCare is the largest operator of funeral homes, cemeteries and crematoria in Australia and New Zealand, with operations in Singapore. Created in 2001, it floated on the ASX in 2003.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$12.56

02 Oct
2023

-0.030

OPEN

$12.57

-0.24%

HIGH

$12.60

145,279

LOW

$12.56

TARGET
$11.948 -4.9% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ALD . MMM . PFP . WES .
FNARENA'S MARKET CONSENSUS FORECASTS
IVC: 1
Title FY21
Actual
FY22
Actual
FY23
Forecast
FY24
Forecast
EPS (cps) xxx - 1.3 33.6 xxx
DPS (cps) xxx 24.5 19.4 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx 16.7% - 21.0% xxx
PE Ratio xxx N/A 37.4 xxx
Dividend Yield xxx N/A 1.5% xxx
Div Pay Ratio(%) xxx N/A 57.6% xxx

Dividend yield today if purchased 3 years ago: 2.49%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

1.95

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 01/09 - ex-div 13.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx-1.3
DPS All xxxxxxxxxxxxxxx24.5
Sales/Revenue xxxxxxxxxxxxxxx588.9 M
Book Value Per Share xxxxxxxxxxxxxxx380.2
Net Operating Cash Flow xxxxxxxxxxxxxxx69.7 M
Net Profit Margin xxxxxxxxxxxxxxx-0.31 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx-0.32 %
Return on Invested Capital xxxxxxxxxxxxxxx-0.20 %
Return on Assets xxxxxxxxxxxxxxx-0.10 %
Return on Equity xxxxxxxxxxxxxxx-0.32 %
Return on Total Capital xxxxxxxxxxxxxxx6.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-29.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201720182019202020212022
Short-Term Debt xxxxxxxxxxxxxxx21 M
Long Term Debt xxxxxxxxxxxxxxx362 M
Total Debt xxxxxxxxxxxxxxx383 M
Goodwill - Gross xxxxxxxxxxxxxxx261 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx32 M
Price To Book Value xxxxxxxxxxxxxxx2.90

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201720182019202020212022
Capex xxxxxxxxxxxxxxx63.3 M
Capex % of Sales xxxxxxxxxxxxxxx10.76 %
Cost of Goods Sold xxxxxxxxxxxxxxx423 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx101 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx6 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

10/08/2023

-1

No Rating

-

InvoCare has entered into a scheme implementation deed with TPG for the latter to acquire all shares for $12.70 cash. This includes a fully franked special dividend of up to $0.60.

UBS points out the background is challenging and market volumes have softened with the impact of the flu season in 2023 comparatively benign, to date.

Despite negative margin impacts from operating deleverage on the back of weaker volumes and ongoing inflation, the broker observes volatility has reduced in the first half and case averages have remained strong.

UBS is currently restricted on providing a rating or target.

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

IVC STOCK CHART